The Fifth Meeting on Access to Medicines under Universal Health Coverage in the Asia Pacific Region
Strategies for better access - What works?

The Imperial Hotel, New Delhi, India, 19-20 September 2018

Provisional Programme

Goal:

Facilitate the exchange of information and experiences on the use of pricing, procurement and other policies, tools, skills to expand access to essential medicines

Specific Objectives:

1. To share information on managing medicines prices and ensuring affordability to improve access, especially on low-middle income country settings; including high price innovative therapies

2. Develop knowledge and skills to improve efficiency of procurement and price negotiations

3. To promote exchange of experience between countries on the policies and strategies used to lower prices and make medicines more affordable

Participating countries:

Country		Country		Country		Country	
Bangladesh		India		Mongolia		Singapore	
Bhutan		Indonesia		Myanmar		Sri Lanka	
Brunei Darussalam		Lao PDR		Nepal		Thailand	
Cambodia		Malaysia		Philippines		Timor-Leste	
China		Maldives		Republic of Korea			

Supporting Organizations:

OECD, WHO HQ, WHO SEARO, WHO WPRO

Day 1. Global and Regional updates and review of Asia Pacific pharmaceutical policies for improving access	
8:30 – 9:00	Registration of participants *(Conference lobby area)*
Opening session	
9:00-10:15	Opening remarks *(Dr Poonam Khetrapal Singh, Regional Director, WHO SEARO)* Opening remarks *(Mr Maeng Ho-Young, Director General, OECD Korea Policy Center)* Keynote presentation: "Universal Health Coverage, Health Systems and Access to Medicines" *(Professor Soonman Kwon, Seoul National University)* Background and Meeting Objectives *(Dr Socorro Escalante, WHO WPRO and Dr Klara Tisocki, WHO SEARO)* Appointment of Chair, Co-chair and Rapporteur Administrative announcements
10:15-10:45	Group photo followed by tea & coffee
Session 1. Access to medicines: A changing agenda regionally and globally	
10:45-13:00	Recent progress in the South East Asia region on access to medicines and moving towards UHC *(Dr Klara Tisocki, WHO SEARO)* Recent progress in the Western Pacific region on access to medicines and moving towards UHC *(Dr Socorro Escalante, WHO WPRO)* Global update on WHO's work on improving access to medicines in context of SDGs and supporting countries for UHC *(Dr Sarah Garner, WHO HQ)* Updates on OECD's work in the Asia Pacific Region: Health at a Glance Asia Pacific 2018 edition *(Mr Luca Lorenzoni, OECD)* Impact of trade, intellectual property and regulation on access to medicines – opportunities for collaboration *(Dr Manisha Shridhar, WHO SEARO)*
13:00-14:00	Lunch
Session 2. Opportunities for getting better value and better coverage	
14:00-15:15	Value in pharmaceutical pricing – key lessons learnt from OECD country experiences *(Ms Valérie Paris, OECD)* Options for improving access to cancer medicines through better selection *(Dr Klara Tisocki)* The role of HTA and moving towards fair pricing *(Dr Andrew Rintoul, WHO HQ)* Issues & challenges of costly new oncology medicines *(Professor SeungJin Bae, College of Pharmacy, Ewha Womans University, Republic of Korea)*
15:15–15:30	Tea/coffee break
Session 3. Options for improving price transparency	
15:30-17:00	Price negotiation of high-cost medicines *(Professor Eun-young Bae, School of Pharmacy, Gyeongsang National University, Republic of Korea)* Price transparency and using PIEMEDS as platform for price comparisons Actions to improve price transparency in Asia Pacific region *(Group discussion)*
19:00-21:00	**Reception – *Imperial Hotel lawns***

Agenda: Thursday, 20 September 2018

DAY 2. Moving forward: What actions are needed and feasible by countries?	
Session 4. Progress, challenges and lessons learned in countries	
8:30-10:15	Country Updates: *Bangladesh, Philippines, Republic of Korea, Sri Lanka, Thailand*
10:15-10:30	Tea/coffee break or participants take refreshments to group discussions
10:30 13:00	**Interactive clinics on how to get better prices for medicines** *Group discussions* Topic 1. Getting better prices through effective pricing or innovative procurement Topic 2. Negotiating prices of high cost medicines Topic 3. How to use HTA when adding new medicine to national essential medicines lists, reimbursement lists *Experts rotate around all three groups*
13:00-14:00	Lunch
Session 5. Strategies to address challenges as individual countries and collaboratively	
14:00-15:30	**Parallel group discussions** Group A. How can *bilateral* collaboration multi- country collaboration in developing pricing policies can assist countries? Group B. How can we better evaluate what works? What type research evaluation etc. needed to determine if medicines pricing related interventions achieved intended outcomes? Group C. Tracking indicators to monitor access to medicines in the Asia Pacific Region: what should be measured and how?
15:00-15:30	Tea/coffee break
15:30-16:00	Feedback from Group A-C
Session 6. Ways forward on collaboration via this network	
16:00-16:30	**Plenary session for prioritization of actions put forward via the network** • Actions at country level • Coordinated bilateral or bioregional regional actions • Actions for consideration of WHOCC, OECD and needs of supporting research
16:30-17:00	**Summary session** • Summary of what we learnt *Dr Socorro Escalante* • Summary what we planned *Dr Klara Tisocki* • Support by OECD *Mr Luca Lorenzoni* • Supporting research and evaluation *Professor Soonman Kwon* • Final closing remarks *Mr. Maeng Ho-Young*
Notes:	

ACCESS TO ESSENTIAL MEDICINES IS A KEY COMPONENT OF UNIVERSAL HEALTH COVERAGE

SDG3 TARGET 3.8:

Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all

Source: United Nations. Transforming our world:
The 2030 Agenda for Sustainable Development, 2015.